Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

Under direction of Health Secretary Robert F. Kennedy Jr., the CDC is considering changes to its recommendations on vaccines ...

As spring temperatures rise along with pollen counts in Georgia, the state is seeing a decline in winter respiratory ...

This year's flu season has become the state's deadliest in nearly a decade, with at least 388 deaths so far. Meanwhile, flu ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

(AP Photo/David Zalubowski, File) FILE - This electron microscope image provided by the National Institutes of Health shows ...

Doctors say the flu season may arrive and peak earlier this year. More than 48,000 confirmed cases of influenza have already been recorded in Australia in 2025. Doctors say now is the best time to ...

The rate of acute respiratory illness causing people to seek healthcare remains high, according to the Centers for Disease Control (CDC) While viruses like the flu, RSV and COVID can impact people ...